Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.
about
Efavirenz and the CNS: what we already know and questions that need to be answeredPharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypesAIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000-2008: hospital-based cohort studiesSubstantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers.Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.Tolerability of central nervous system symptoms among HIV-1 infected efavirenz users: analysis of patient electronic medical record data.HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009-2014.An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS PatientsEfavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation.Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.Antitumor effect of combination of the inhibitors of two new oncotargets: proton pumps and reverse transcriptase.A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications.Can voluntary pooled procurement reduce the price of antiretroviral drugs? a case study of Efavirenz.Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen.Discontinuation of Efavirenz in Paediatric Patients: Why do Children Switch?Efavirenz is related to neuropsychiatric symptoms among adults, but not among adolescents living with human immunodeficiency virus in Kilimanjaro, Tanzania.Effect of concomitant use of montelukast and efavirenz on neuropsychiatric adverse events.Neurological Complications of HIV Infection.Emerging reverse transcriptase inhibitors for HIV-1 infection.High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily
P2860
Q28085028-92A0F2B7-56D1-493D-94BD-1E78356D65C4Q31150044-B778CCB4-A0D9-49B3-9B97-D5F073CD871EQ33656320-4658A632-56BF-464F-930E-0BCA92529A58Q34404878-90E15ED3-EA7E-4D58-B02C-23468071DB99Q34536677-2A3A7794-6875-403C-895B-43EEEA0535DAQ36266624-1C28BCAE-0308-4FED-87B6-06D5C4BEEF6AQ36282702-D120794D-EEEB-4821-B27A-2447037EDAC8Q36437792-39E4D5A5-129D-4010-A414-2F8C46160388Q37538717-CFDE99FD-E30D-45AA-AB3A-44B5C16EC49FQ37538760-5FFF0DC6-B32E-49E3-B7DE-A95E5ADAF23BQ37706150-DC972DAF-40DA-4ADA-8B48-BAB1F96587FCQ38743628-E4829689-4278-48A9-862A-7939361097C6Q39040089-1D18830A-2417-4D18-942D-3E5BD582AEF1Q40513800-D55B2163-914A-45B1-92E6-2AEE48104E9DQ47404336-277CF1B6-65C0-423D-9918-2CA7FE5D770BQ47567926-FEB9A6AE-F356-4708-997D-1FE7680AE9AFQ48142521-E2EF95CA-82F1-4E77-92D0-80281A2948DDQ52774286-5D154ECB-9AC3-4674-8A73-93375E92096BQ53686168-4FAA9013-8878-4CC3-8B02-4B41FCC2B518Q56910903-0F25EDA8-768B-4233-928F-7CD1A1C95C36
P2860
Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Discontinuation of efavirenz t ...... ropsychiatric adverse effects.
@en
type
label
Discontinuation of efavirenz t ...... ropsychiatric adverse effects.
@en
prefLabel
Discontinuation of efavirenz t ...... ropsychiatric adverse effects.
@en
P2093
P2860
P1476
Discontinuation of efavirenz t ...... ropsychiatric adverse effects.
@en
P2093
Carsten Schade Larsen
Chalotte Stecher
Peter Derek Christian Leutscher
P2860
P304
P356
10.3109/00365548.2013.773067
P577
2013-02-21T00:00:00Z